Clinical trials · Boston, MA
Lung cancer clinical trials in Boston
We’re tracking 178 recruiting lung cancer studies with a site in or near Boston — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Boston
- NCT06855771RecruitingPhase 2
Study of an oral drug for MTAP-deleted advanced lung cancer
This study tests an experimental oral medication (navlimetostat) for people with advanced lung cancer whose tumors have a specific genetic change called an MTAP deletion. It’s for those whose cancer has progressed after earlier treatments.
Boston, MassachusettsAges 18 years+ - NCT06561685RecruitingPhase 1
Study of LY4050784 for Advanced Solid Tumors with SMARCA4 Changes
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
Boston, MassachusettsAges 18 years+ - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT07132190RecruitingPhase 2
Radiation for growing brain tumors with same-day planning
This study tests whether a precise, one-day radiation treatment for brain tumors that are growing or in tricky spots can be effective with a smaller safety margin. It's designed for people whose brain tumors are changing quickly or sitting near areas of swelling or recent surgery.
Boston, MassachusettsAges 18 years+ - NCT07155174RecruitingPhase 2
Testing new drug combo for first-line extensive small cell lung cancer
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
Boston, MassachusettsAges 18 years+ - NCT04787042RecruitingPhase 1/Phase 2
Safety and early benefits of ST-067 for advanced solid tumors
This early-stage trial tests ST-067 to see if it is safe and whether it may shrink advanced cancers. It also looks at how the drug moves through the body and affects the immune system.
Boston, MassachusettsAges 18 years+ - NCT06162221RecruitingPhase 1/Phase 2
Study of RAS inhibitors for advanced RAS-mutated lung cancer
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07227623Recruiting
Digital health program to help lung cancer survivors get active
This trial tests a digital health tool to help lung cancer patients improve their physical function and wellness during and after treatment. It is designed for people with early-stage lung cancer who are starting treatment with chemotherapy, immunotherapy, or radiation.
Boston, MassachusettsAges 18 years+ - NCT05753722RecruitingPhase 1
First trial for PRTH-101 alone or with pembrolizumab
This early study tests PRTH-101, given by itself or with pembrolizumab, in people with advanced cancers that have spread or cannot be removed by surgery. The goal is to see if it is safe and how it affects the cancer.
Boston, MassachusettsAges 18 years+ - NCT06835569RecruitingPhase 1
ALTA3263 for advanced KRAS-mutated solid tumors
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
Boston, MassachusettsAges 18 years+ - NCT06810544RecruitingPhase 1/Phase 2
Study of TNG456 for tumors with MTAP loss
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT06910956Recruiting
Finding high-risk patients for lung cancer screening using chest X-rays
This trial uses artificial intelligence to analyze chest X-rays and identify people who may be at high risk for lung cancer and could benefit from a CT screening scan. It's designed for current or former smokers aged 50 to 77 who have had a recent chest X-ray and are not already being checked for lung cancer.
Boston, MassachusettsAges 50–77 - NCT04267848RecruitingPhase 3
Testing immunotherapy with chemo after lung cancer surgery
This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.
Boston, MassachusettsAges 18 years+ - NCT02984761Recruiting
Surgery vs focused radiation for early lung cancer
This trial compares two ways to treat early-stage lung cancer: surgery or a precise type of radiation called stereotactic radiotherapy. It aims to find out which approach works best for people whose cancer is small and has not spread.
Boston, MassachusettsAges 18 years+ - NCT07307157Enrolling by invitation
AI vs. pathologists: Which diagnoses cancer better?
This study tests a new AI system called COSMO against pathologists to see which is better at diagnosing cancer from digital slides. If you are an experienced pathologist, you will review slides independently, and your results will be compared with the AI's.
Boston, MassachusettsAges Any age - NCT06899126RecruitingPhase 3
Study of a drug combo for first-line HER2-positive lung cancer
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
Boston, MassachusettsAges 18 years+ - NCT04789486RecruitingPhase 1/Phase 2
MR-guided radiation plus nanoparticles for central lung or pancreatic tumors
This early-phase study tests a new way to deliver focused radiation using MRI guidance and tiny particles, aiming to treat certain central lung tumors or locally advanced pancreatic cancer. It’s designed to see how safe it is and how well it can control these tumors.
Boston, MassachusettsAges 18 years+ - NCT07195695RecruitingPhase 3
Zongertinib after surgery for HER2-mutated lung cancer
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Boston, MassachusettsAges 18 years+ - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
Boston, MassachusettsAges 18 years+ - NCT07361497RecruitingPhase 3
New Drug vs Standard Drug After Chemoradiation for Stage 3 Lung Cancer
This study tests a new drug, pumitamig, against an older drug, durvalumab, for people with stage 3 non-small cell lung cancer that cannot be removed by surgery and has not progressed after chemotherapy and radiation. The goal is to see which drug works better to keep the cancer from growing.
Boston, MassachusettsAges 18 years+ - NCT05463796Recruiting
Prevention and early detection for people at high cancer risk
This study looks at surveillance (watching closely), prevention, and early “interception” steps to lower the chance that cancer will develop or be found later. It is for people with genetic risk, past cancer treatment exposures, strong family history, or certain early pre-cancer or high-risk conditions.
Boston, MassachusettsAges Any age - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Boston, MassachusettsAges 18 years+ - NCT06769126RecruitingPhase 2
Personalized treatment study for extensive stage small cell lung cancer
This study uses biomarker tests on your tumor to find a personalized treatment after initial chemotherapy. You will be assigned to one of four treatment groups based on your biomarker results.
Boston, MassachusettsAges 18 years+
Hear when a new Lung cancer trial opens near Boston, MA
We’ll email you when one opens near Boston, MA — at most once a week, no account needed, unsubscribe anytime.
Lung cancer trials in other cities
Where these studies are running near Boston
Institutions with a site for the recruiting lung cancer studies listed above.
- Dana-Farber Cancer Institute · 11 studies
- Massachusetts General Hospital · 7 studies
- Brigham and Women's Hospital · 2 studies
- Lahey Hospital and Medical Center · 2 studies
- Lahey Medical Center-Peabody · 2 studies
- Addison Gilbert Hospital
- Beth Israel Deaconess Medical Center
- Beth Israel Deaconess Medical Center/Winchester Center for Cancer Care
What taking part in a lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting lung cancer studies in Massachusetts.
Common questions
- Are there lung cancer clinical trials near Boston?
- Yes. We're currently tracking 178 recruiting lung cancer studies with a site near Boston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer study near Boston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Boston to take part?
- Not necessarily. These studies have a site near Boston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer studies open near Boston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.